Few Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock
Earnings Growthhistorical EPS growth rate for BioSpecifics is 32.5%, investors should actually focus on the projected growth. The company's EPS is expected to grow 10.3% this year, crushing the industry average, which calls for EPS growth of 5.2%
Cash Flow GrowthRight now, year-over-year cash flow growth for BioSpecifics is 53.3%, which is higher than many of its peers. In fact, the rate compares to the industry average of 10.4%.
Promising Earnings Estimate RevisionsThere have been upward revisions in current-year earnings estimates for BioSpecifics. The Zacks Consensus Estimate for the current year has surged 8.3% over the past month.
Bottom LineBioSpecifics has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #1 because of the positive earnings estimate revisions.